drugset / Trial / NCT02085655
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.
Timeline
- Start
- 2013-04-25
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Methotrexate | Small molecule | 3000 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2000 mg/m2 | Intramuscular |
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |